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Expeditious Synthesis of 1,1-Diarylethylenes Related to 
Isocombretastatin A-4 (isoCA4) via Palladium-Catalyzed 
Arylation of N-Tosylhydrazones with Aryl Triflates 
Bret Tréguier, Abdallah Hamze, Olivier Provot, Jean-Daniel Brion and Mouâd Alami*
Univ Paris-Sud, CNRS, BioCIS UMR 8076, Laboratoire de Chimie Thérapeutique, Faculté de Pharmacie, 5 rue J.-B. Clément, Châtenay-
Malabry, F-92296, France. 
Abstract—. A quick and efficient entry to 1,1-diarylethylenes via the reaction of poly-oxygenated aryl N-tosylhydrazones with aryl 
triflates is described. The reaction employs the catalytic system Pd(OAc)2/XPhos, tBuOLi as the base and dioxane as the solvent. A variety 
of substituents on both coupling partner’s hydrazones and triflates are tolerated. This procedure provides a complementary route to the 
existing methods for the access to 1,1-diarylethylenes of biological interest. 
——— 
* Corresponding author. Tel.: +33-1-46.83.58.87; fax: +33-1-46.83.58.28; e-mail: mouad.alami@u-psud.fr 
Keywords: Aryl triflates, tosylhydrazones, palladium, Xphos ligand, 1,1-diarylethylenes, isocombretastatin A-4. 
Combretastatins CA-4 and CA-1 are a very interesting 
class of cytotoxic agents of natural origin, which have 
received much attention due to their simple structures, 
their high potency as cytotoxic and antimitotic agents as 
well as their ability to selectively damage tumor 
neovasculature1 Despite their remarkable anticancer 
activities, these Z-stilbene compounds are prone to double 
bond isomerization during storage and administration.2 
The E-isomers display dramatically reduced inhibition of 
cancer cell growth and tubulin assembly.3 A number of 
structure-activity relationships (SARs) have been reported 
for the combretastatins.4 These studies revealed that the 
3,4,5-trimethoxyphenyl unit as well as the cis orientation 
of the two aromatic rings is a prerequisite for significant 
biological activities. Therefore, extensive studies have 
been conducted to prepare various cis restricted analogues 
by inserting mainly the cis-olefin in a five-membered 
heterocyclic ring (e.g.; pyrazoles, thiazoles, triazoles, 
imidazoles, ...).5 
Our interest in 1,1-diarylethylene unit synthesis,6,7
combined with our efforts to discover novel potent tubulin 
assembly inhibitors, related to CA-4,8 led us to identify a 
promising class of substances with strong anticancer 
activities, simply by switching the trimethoxyphenyl 
nucleus from the C(1) to the C(2) position of the ethylene 
bridge.9 In contrast to their natural parent combretastatins 
A, these synthetic isomers, named isocombretastatins A 
(isoCA), are easy to synthesize without the need to 
control the olefin geometry and constitute the simplest 
isomers of isoCA. The most active compound isoCA-4 
appears to elicit its tumor cytotoxicity in a fashion similar 
to CA-4, via inhibition of tubulin polymerization, which 
then leads to cell cycle arrest in G2/M. As the 
replacement of the 1,2-ethylene bridge by the 1,1-ethylene 
one resulted in retention of biological activity, our finding 
encouraged us to use this bioisostere10 in future structure 
activity relationship studies. To this end, a set of 
compounds derived from the general structures 1 were 
considered (Figure 1), and a versatile synthesis that would 
allow the incorporation of a variety of aryl substituents 
was therefore needed. 
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Figure 1. Combretastatins A-1, A-4, synthetic tubulin 
polymerization inhibitor isoCA-4 and target structure 1. 
Typically, the synthesis of the most active compound 
isoCA-4 was performed by the reaction of 3,4,5-
trimethoxyacetophenone N-tosylhydrazone11 2a with 2-
tbutyldimethylsilyloxy-4-iodoanisole. Thus, when using 
Pd2(dba)3 (10 mol%) as a catalyst and Xphos (20 mol%) 
as a ligand, the coupling reaction gave the desired product 
isoCA-4 in a 75% yield.12 This synthetic approach proved 
to be suitable for the synthesis of the others 
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isocombretastatins A-1 to A-59a since no stoichiometric 
organometallic reagent was employed and also, in view of 
the simple transformation of the acetophenones into their 
corresponding N-tosylhydrazones. Although this reaction 
has been investigated with aryl halides,9a,11 there is no 
report employing the use of aryl triflates. Extension of 
this coupling reaction to include aryl triflates as 
electrophiles13 is especially important since these 
substrates can be easily synthesized from phenol sources 
and consequently can be revealed at a late stage in a 
synthetic sequence. The commercial availability of phenol 
derivatives will make this approach sufficiently diversity 
oriented, thus fulfilling the recent demand for the 
generation of large combinatorial chemical libraries. 
Herein we report our studies in the synthesis of 1,1-
diarylethylenes 1 from the coupling of polyoxygenated N-
tosylhydrazone 2 with aryl triflates. 
Initial studies were performed by coupling 3,4,5-
trimethoxyacetophenone N-tosylhydrazone (2a) and aryl 
triflate 3a, as model substrates using Pd2(dba)3 (5 mol%), 
Xphos (10 mol%) and tBuOLi (2 equiv) in dioxane at 90 
°C. Under these conditions (conventional atmospheric 
pressure reaction), 1a was formed in a modest 54% yield 
(entry 1). Fortunately, a much higher yield was obtained 
under pressure by running the reaction in a sealed tube 
(84%, entry 2). As summarized in Table 1, the nature of 
the base has an influence on the outcome of the reaction. 
tBuOLi appeared the base of choice to secure the 1,1-
diarylethylene 1a formation since performing the same 
reaction with tBuOK, Cs2CO3 or K3PO4 lead to lower 
yields (entries 3-6). The screening was continued with 
respects to palladium source and ligands. We were 
pleased to find that the catalytic activity of Pd(OAc)2 or 
PdCl2(MeCN)2 proved to be similar to Pd2(dba)3 leading 
to 1a with excellent yields (89-91%, entries 9 and 10). 
Pd/C or Pd(OH)2 however, showed moderate catalytic 
activities (entries 7 and 8) since 1a was formed with 
lower yields than those obtained with Pd(OAc)2 or 
PdCl2(MeCN)2. Evaluation of ligands revealed that Xphos 
(L3) and CyJohnPhos (L1) have a similar efficiency and 
are superior to all other choices (entries 11-13). Finally 
we examined the effect of the leaving group (LG) of the 
electrophilic coupling partner. A comparative study 
revealed that the reactivity of triflate 3a is superior to that 
of imidazolylsulfonate 3b (entry 14) and nonaflate 3c 
(entry 15) whereas the coupling failed when using 
tosylate 3d (entry 16). Considering its high catalytic 
activity Pd(OAc)2 was our choice for further 
experimentation. In summary, the best conditions were 
found to require: 2a (1 equiv), 3a (1 equiv), Pd(OAc)2 (5 
mol%), Xphos (10 mol%), tBuOLi ( 2 equiv), dioxane in 
a sealed tube at 90 °C for 3 h.14 It should be noted that 
microwave heating is also effective for this reaction. 
However, if the reaction time is reduced (~0.5 h),15 a 
slightly lower yield (78%) was obtained. 
Table 1. Initial studies for Pd-Catalyzed Barluenga 
Coupling of N-tosylhydrazone 2a with 3.a  
PCy2
iPrPri
iPr
PCy2
OMeMeO
PCy2
PtBu2
iPrPri
iPr
L1: CyJohnPhos L2: S-Phos L3: XPhos L4: tBuXPhos
NNHTs
MeO
MeO
OMe
+
MeO
MeO
OMe
OMe
LG
OMe
[Pd] (5 mol%)
Ligand (10 mol%)
base
1,4-dioxane
90 °C2a 3 1a
3a: LG = OTf
sealed tube
3b: LG = Im (Im = Imidazolylsulfonate)
3d: LG = OTs
3c: LG = ONfF
Entry [Pd] / Ligand LG Base Yieldb 
(%) 
1 Pd2(dba)3 / L3 OTf tBuOLi 54c 
2 Pd2(dba)3 / L3 OTf tBuOLi 84 
3 Pd2(dba)3 / L3 OTf tBuOK 34 
4 Pd2(dba)3 / L3 OTf Cs2CO3 23 
5 Pd2(dba)3 / L3 OTf K3PO4 50 
6 Pd2(dba)3 / L3 OTf Li2CO3 0 
7 Pd/C / L3 OTf tBuOLi 13 
8 Pd(OH)2/C / L3 OTf tBuOLi 30 
9 PdCl2(MeCN)2 / L3 OTf tBuOLi 89 
10 Pd(OAc)2 / L3 OTf tBuOLi 91 
11 Pd(OAc)2 / L1 OTf tBuOLi 82 
12 Pd(OAc)2 / L2 OTf tBuOLi 55 
13 Pd(OAc)2 / L4 OTf tBuOLi 19 
14 Pd(OAc)2 / L3 OSO2Im tBuOLi 70 
15 Pd(OAc)2 / L3 ONfF tBuOLi 52 
16 Pd(OAc)2 / L3 OTs tBuOLi 5 
a All reactions were heated in a sealed tube in dioxane using 2a (1 
equiv), 3 (1 equiv), [Pd] (5 mol%), Ligand (10 mol%) and base (2 equiv) 
at 90 °C for 3 h. 
b Isolated yield of 1a. 
c Reaction was performed at 90 °C at atmospheric pressure. 
Table 2. Synthesis of 1,1-diarylethylene 1a 
Entry Hydrazone 2 ArOTf 3 Product 1 
Yieldb 
(%) 
1 
NNHTs
OMe
MeO
MeO
OTf
OMe
MeO
OMe
MeO
OMe
91 
2a 3a 1a 
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NNHTs
OMe
MeO
MeO
 
OTf
 MeO
OMe
MeO
 
90 
 2a 3e 1b  
3 
NNHTs
OMe
MeO
MeO
 
OTf
OMe  MeO
OMe
MeO
OMe  
75 
 2a 3f 1c  
4 
NNHTs
OMe
MeO
MeO
 
OTf
Cl  
MeO
OMe
MeO
Cl
 
69 
 2a 3g 1d  
5 
NNHTs
OTBDMS
MeO
 
OTf
 
OTBDMS
MeO
 
94 
 2b 3e 1e  
6 
NNHTs
OTBDMS
MeO
 
OTf
OMe  OTBDMS
MeO
OMe
 
97 
 2b 3a 1f  
7 
NNHTs
OTBDMS
TBDMSO
 
OTf
 
OTBDMS
TBDMSO
 
90 
 2c 3e 1g  
8 
NNHTs
OTBDMS
TBDMSO
 
OTf
OMe  OTBDMS
TBDMSO
OMe
 
74 
 2c 3a 1h  
9 
NNHTs
OMe
MeO
MeO
 
TfO
O
O
 
MeO
OMe
MeO
O
O  
75 
 2a 3f 1i  
10 
NNHTs
OMe
MeO
MeO
 
O
O
TfO
 
MeO
OMe
MeO
O
O  
66 
 2a 3g 1j  
11 
NNHTs
OMe
MeO
MeO
 
N
OTf
 MeO
OMe
MeO
N
 
52c 
 2a 3e 1k  
a All reactions were heated in a sealed tube in dioxane using 2a (1 
equiv), 3 (1 equiv), Pd(OAc)2 (5 mol%), XPhos (10 mol%) and tBuOLi 
(2 equiv) at 90 °C for 3 h. 
b Isolated yield of 1. 
c Not optimized. 
After these optimization studies, we applied this catalytic 
system for the coupling of various aryl triflates and 
polyoxygenated tosylhydrazones 2 to assess the scope of 
the developed reaction conditions (Table 2). First, 3,4,5-
trimethoxyacetophenone N-tosylhydrazone 2a was 
reacted with various aryl triflates 3 to afford the 
corresponding 1,1-diarylethylenes 1a-c (entries 1-3). 
Running the reaction from aryl triflate 3g bearing a para 
sp2-carbon-chlorine bond, the coupling reaction gave 
selectively 1d in a 69% yield (entry 4). Among these 
substrates, the coupling reaction worked efficiently even 
in the case of alkaline sensitive tosylhydrazones 2b and 2c 
bearing silyloxy groups in good to excellent yields 
(entries 5-8). Heteroaromatic triflates 3f-e also were 
coupled successfully with hydrazone 2a and provided the 
desired coupling products 1i-k in a satisfactory yields 
(entries 9-11), despite the fact that the reaction conditions 
with these heterocyclic substrates had never been 
optimized. 
In conclusion, we have described an efficient and general 
method for cross coupling of different aryl triflates with 
polyoxygenated hydrazones catalyzed by the combination 
of Pd(OAc)2 or PdCl2(MeCN)2 and Xphos ligand in the 
presence of tBuOLi as base in a sealed tube. In our 
opinion, this approach seems to be a suitable method for 
the synthesis of others isocombretastatin A analogues. 
The design of antitumor agents based on the 1,1-
diaryethylene scaffold in future structure-activity 
relationship studies is currently underway; the results of 
synthetic and biological studies will be reported in due 
course. 
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 Diarylethylene 1a: Yield: 91%. Rf (cyclohexane/EtOAc : 6/4) = 
0.60. IR (cm-1): 1579, 1507, 1454, 1411, 1346, 1299, 1233, 1174, 
1122, 1030, 1004. 1H RMN: ( ppm, CD3COCD3, 300 MHz): 3.75 
(s, 3H, OCH3), 3.78 (s, 6H, OCH3), 3.82 (s, 3H, OCH3), 5.34 (m, 
2H, CH2), 6.60 (s, 2H), 6.92 (d, 2H, J = 8.7 Hz), 7.29 (d, 2H, J = 8.7 
Hz). 13C NMR ( ppm, 75 MHz, CD3COCD3): 55.5, 56.4 (2), 60.5, 
106.8 (2), 112.7, 114.4 (2), 130.1 (2), 134.4, 138.2 (2), 150.6, 154.1 
(2), 160.5.  
 Diarylethylene 1d: Yield: 69%. Rf (cyclohexane/EtOAc : 9/1) = 
0.58. IR (cm-1): 1579, 1504, 1462, 1410, 1344, 1235, 1125, 1007. 1H 
RMN: ( ppm, CDCl3, 300 MHz):3.73 (s, 6H, OCH3), 3.80 (s, 3H, 
OCH3), 5.34 (d, 2H, J=1.0Hz, CH2), 6.44 (s, 2H, CH), 7.22 (s, 4H, 
CH). 13C NMR ( ppm, 75 MHz, CDCl3): 56.1 (2), 60.9, 105.5 (2), 
114.3, 128.4 (2), 129.6 (2), 133.7, 136.8, 137.8, 139.7, 149.0, 153.0 
(2).  
 Diarylethylene 1i: Yield: 75 %..Rf (cyclohexane/EtOAc : 7/3) = 
0.28. Mp: 143-145 °C. IR (cm-1) : 1719, 1574, 1508, 1453, 1411, 
1350, 1221, 1177, 1124, 996. 1H RMN: (ppm, CDCl3, 300 MHz): 
3.82 (s, 6H), 3.89 (s, 3H), 5.54 (s, 1H), 5.56 (s, 1H), 6.42 (d, 1H, 
J=9.5Hz), 6.51 (s, 2H), 7.27 (dd, 1H, J=1.6Hz, J=8.0Hz), 7.35 (d, 
1H, J=1.5Hz), 7.44 (d, 1H, J=8.0Hz), 7.71 (d, 1H, J=9.5Hz).13C 
NMR ( ppm, 75 MHz, CDCl3): 56.0 (2), 60.8, 105.6 (2), 116.1, 
116.2, 116.4, 118.2, 124.3, 127.4, 136.0, 138.1, 142.9, 145.1, 148.6, 
153.0 (2), 153.9, 160.6.  
15  The reaction was conducted according to the general method 
described above. The reaction vessel was sealed, then placed in the 
Emrys Optimizer and exposed to microwave irradiation according to 
the following specifications: temperature: 120 °C; time: 30 min; 
fixed hold time: on; sample absorption: high; pre-stirring: 60 s. 
